IRDye 800CW RGD Optical Probe is a BrightSite™ near-infrared (NIR) fluorescently-labeled RGD imaging agent specifically designed to target the overexpression of integrins on tumors.
Integrins are cell surface heterodimeric glycoproteins involved in cell-to-cell and cell-to-matrix interactions. IRDye 800CW RGD Optical Probe is composed of the recognition motif, RGD (Arg-Gly-Asp), a tripeptide sequence used to bind integrin receptors including αvβ3. This receptor class is involved in tumor growth, tumor invasiveness, metastasis, tumor induced angiogenesis, inflammation, osteoporosis, and rheumatoid arthritis.
Interest in using a labeled RGD peptide ligand for the study and/or monitoring of diseases related to the αvβ3 receptor over-expression is increasing. Several groups have labeled RGD successfully with fluorescent dyes for in vitro and in vivo imaging.
Absorbance and Emission Spectra
- Huang, R., Vider, J., Kovar, J. L., Olive, D. M., Mellinghoff, I. K., Mayer-Kuckuk, P., … Blasberg, R. G. (2012). Integrin αvβ3-targeted IRDye 800CW near-infrared imaging of glioblastoma. Clinical Cancer Research, 18(20), 5731–5740. doi: 10.1158/1078-0432.CCR-12-0374.